Eptinezumab improves outcomes, lowers medication use in patients with chronic migraine and medication-overuse headache
21 Aug 2020
byRoshini Claire Anthony
In patients diagnosed with chronic migraine and medication-overuse headache (MOH), treatment with eptinezumab led to improved patient-reported outcomes, fewer migraine days, and a reduction in acute medication use, according to subgroup analyses of the PROMISE-2* trial presented at AHS 2020.